William Ho, President and CEO, Co-founder, IN8bio
William has 19 years of experience in the biotechnology and healthcare industries. He founded Incysus Therapeutics from AlephPoint Capital, a private healthcare focused investment manager which he launched in 2014. Prior to AlephPoint, Will launched the public investments and cross-over portfolio at New Leaf Venture Partners, a leading healthcare venture capital firm. He was a Senior Equity Research Analyst at Bank of America and an Analyst at Piper Jaffray & Company covering the biotechnology and life-science tools sectors. He was Institutional Investor's All-America Research Team Best Up-and-Comer in 2008. Earlier in his career, he led operational and financial analysis at CuraGen Corporation, one of the leading genomics era companies, where he restructured the company and was an Associate on the Healthcare Investment banking team at Cowen & Co.
Will holds an MBA from the University of Notre Dame and a BS in Biochemistry, with honors from McMaster University in Canada.